Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity

Hiroaki Muguruma(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Makoto Kawatani(RIKEN Center for Sustainable Resource Science), Hiroyuki Osada(Microbial Chemistry Research Foundation), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Hisanori Uehara(Tokushima University Hospital), Seiji Yano(Kanazawa University Hospital)
Clinical Cancer Research
December 15, 2005
10.1158/1078-0432.ccr-05-1335
Cited by 51

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134